INVESTMENT IN AFFILIATES, AVAILABLE-FOR-SALE EQUITY SECURITIES	12 Months Ended
Dec. 31, 2011
INVESTMENT IN AFFILIATES, AVAILABLE-FOR-SALE EQUITY SECURITIES	4. INVESTMENT IN AFFILIATES, AVAILABLE-FOR-SALE EQUITY SECURITIES Substantially all of the Company’s available-for-sale equity securities are shares of Chimera Investment Corporation (“Chimera”) and CreXus Investment Corp. (“CreXus”) and are reported at fair value. The Company owned approximately 45.0 million shares of Chimera at a fair value of approximately $112.9 million at December 31, 2011 and approximately 45.0 million shares of Chimera at a fair value of approximately $184.9 million at December 31, 2010. At December 31, 2011, the investment in Chimera had an unrealized loss of $25.9 million. The Company owned approximately 9.5 million shares of CreXus at a fair value of approximately $98.9 million at December 31, 2011 and approximately 4.5 million shares of CreXus at a fair value of approximately $59.3 million at December 31, 2010. At December 31, 2011, the investment in CreXus had an unrealized loss of $26.5 million. The Company determined other-than-temporary impairment was not necessary for the years ended December 31, 2011, 2010 and 2009 as the Company has the intent and ability to retain its investments for a period of time sufficient to allow for any anticipated recovery in market value.

INVESTMENT IN AFFILIATES, AVAILABLE-FOR-SALE EQUITY SECURITIES

12 Months Ended

Dec. 31, 2011

INVESTMENT IN AFFILIATES, AVAILABLE-FOR-SALE EQUITY SECURITIES

4. INVESTMENT IN AFFILIATES, AVAILABLE-FOR-SALE EQUITY SECURITIES

Substantially all of the Company’s available-for-sale equity securities are shares of Chimera Investment Corporation (“Chimera”) and CreXus Investment Corp. (“CreXus”) and are reported at fair value. The Company owned approximately 45.0 million shares of Chimera at a fair value of approximately $112.9 million at December 31, 2011 and approximately 45.0 million shares of Chimera at a fair value of approximately $184.9 million at December 31, 2010. At December 31, 2011, the investment in Chimera had an unrealized loss of $25.9 million. The Company owned approximately 9.5 million shares of CreXus at a fair value of approximately $98.9 million at December 31, 2011 and approximately 4.5 million shares of CreXus at a fair value of approximately $59.3 million at December 31, 2010. At December 31, 2011, the investment in CreXus had an unrealized loss of $26.5 million.

The Company determined other-than-temporary impairment was not necessary for the years ended December 31, 2011, 2010 and 2009 as the Company has the intent and ability to retain its investments for a period of time sufficient to allow for any anticipated recovery in market value.